Recombinant Saccharomyces pastorianus Protein RER1 (RER1)

What is the optimal storage condition for Recombinant Saccharomyces pastorianus Protein RER1?

For optimal stability and longevity of Recombinant Saccharomyces pastorianus Protein RER1, storage conditions depend on the protein formulation. Lyophilized RER1 maintains stability for approximately 12 months when stored at -20°C/-80°C, while the liquid form has a shorter shelf life of about 6 months at the same temperature range . To prevent degradation from repeated freeze-thaw cycles, it is recommended to prepare working aliquots that can be stored at 4°C for up to one week . The stability of the protein is influenced by multiple factors including buffer composition, storage temperature, and the intrinsic stability of the protein itself.

What is the recommended reconstitution protocol for lyophilized RER1 protein?

The recommended reconstitution protocol involves:

• Brief centrifugation of the vial prior to opening to bring contents to the bottom

• Reconstitution in deionized sterile water to a concentration of 0.1-1.0 mg/mL

• Addition of glycerol to a final concentration of 5-50% (standard is 50%)

• Aliquoting for long-term storage at -20°C/-80°C

This protocol helps maintain protein stability and activity while minimizing degradation during storage.

What is the structural characterization of human RER1 protein?

Human RER1 is an integral membrane protein consisting of 196 amino acids with four putative transmembrane domains that form an M-shaped topology . Both the N- and C-termini face the cytosol . The protein exhibits structural and functional conservation across species, as evidenced by the ability of human RER1 to complement the RER1 deletion mutant in Saccharomyces cerevisiae . The functional region of RER1 includes a hydrophilic loop between transmembrane domains 2 and 3 (amino acids 89-120), which has been used to generate antibodies for research purposes .

How can RER1 function be studied in cellular trafficking experiments?

To investigate RER1's role in cellular trafficking, researchers should implement multi-faceted approaches:

• Expression Modulation Systems:

  • Overexpression studies using RER1-Myc tagged constructs in mammalian expression vectors

  • RNA interference (siRNA) for RER1 knockdown to assess loss-of-function effects

• Subcellular Localization Analysis:

  • Immunofluorescence microscopy using antibodies against RER1 (such as R75 and R76 polyclonal antibodies)

  • Co-localization studies with ER, Golgi, and secretory pathway markers

• Protein-Protein Interaction Assessment:

  • Co-immunoprecipitation assays to identify RER1 binding partners

  • Proximity ligation assays to confirm interactions in situ

Research has shown that RER1 associates with γ-secretase in early secretory compartments and regulates its intracellular trafficking . Overexpression of RER1 decreases γ-secretase localization on the cell surface, while RER1 knockdown increases the level of cell surface γ-secretase . These experimental approaches can help elucidate the mechanisms by which RER1 functions in protein trafficking.

What methodologies are effective for investigating RER1's role in neurodegenerative disease models?

To study RER1's impact on neurodegenerative pathologies, particularly in relation to alpha-synuclein and amyloid-beta pathology, the following methodologies are recommended:

• In vitro cellular models:

  • Neural cell cultures expressing disease-associated proteins (alpha-synuclein, APP)

  • RER1 overexpression/knockdown coupled with quantification of protein aggregation

• Viral vector approaches:

  • AAV or lentiviral vectors for RER1 expression in affected brain regions

  • Stereotactic delivery methods for targeted expression in animal models

• Quantitative assessments:

  • ELISA-based quantification of secreted amyloid-beta or alpha-synuclein

  • Western blot analysis of mature vs. immature APP levels

  • Cell surface biotinylation assays to measure protein trafficking to plasma membrane

• Functional outcomes:

  • Behavioral testing in animal models following RER1 manipulation

  • Neuropathological assessment of protein aggregation and neurodegeneration

Research has demonstrated that RER1 expression reduces alpha-synuclein levels in cell and neuron cultures , and that RER1 overexpression decreases both γ-secretase localization on the cell surface and Aβ secretion .

How should researchers design experiments to study the interaction between RER1 and the γ-secretase complex?

When investigating RER1-γ-secretase interactions, consider the following experimental design elements:

• Binding site identification:

  • Generate truncation mutants of RER1 to map interaction domains

  • Create chimeric proteins to determine binding specificity

  • Utilize site-directed mutagenesis for point mutations at predicted interface regions

• Functional impact assessment:

  • Measure γ-secretase activity using fluorogenic substrates following RER1 manipulation

  • Quantify secreted Aβ peptides using specialized ELISAs

  • Assess APP processing through western blot analysis of APP C-terminal fragments

• Trafficking dynamics:

  • Implement live-cell imaging with fluorescently tagged RER1 and γ-secretase components

  • Perform subcellular fractionation to track protein movement between compartments

  • Use endoH/PNGase F digestion to assess glycosylation status and trafficking progression

Previous studies have identified RER1 as a binding partner of different γ-secretase subunits, including Nicastrin (NCT) and Presenilin enhancer 2 (PEN2) . RER1 affects γ-secretase assembly by regulating retention or retrieval of γ-secretase subunits, highlighting the importance of proper experimental design to delineate these complex interactions.

What expression systems are optimal for producing functional recombinant RER1 protein?

The selection of expression systems for RER1 production requires careful consideration of protein folding, post-translational modifications, and membrane integration requirements:

What purification strategies yield the highest purity for recombinant RER1?

Achieving high purity RER1 preparations (>85% by SDS-PAGE ) requires strategic purification approaches:

• Initial extraction:

  • For membrane proteins like RER1, detergent selection is critical

  • Mild detergents (DDM, CHAPS) preserve protein structure

  • Optimize detergent concentration through small-scale extractions

• Multi-step purification protocol:

  • Affinity chromatography using tagged constructs (His, GST, etc.)

  • Ion exchange chromatography for charge-based separation

  • Size exclusion chromatography as a polishing step

• Quality control assessments:

  • SDS-PAGE with Coomassie/silver staining for purity estimation

  • Western blotting for identity confirmation

  • Mass spectrometry for molecular weight verification

  • Circular dichroism for secondary structure analysis

How can researchers utilize RER1 to study mechanisms of neurodegenerative diseases?

RER1's involvement in protein trafficking makes it a valuable target for understanding neurodegenerative disease mechanisms:

• Parkinson's disease research:

  • Investigate RER1's effect on alpha-synuclein accumulation and aggregation

  • Test whether viral expression of RER1 in the brain can reduce alpha-synuclein pathology

  • Explore the mechanistic relationship between RER1, alpha-synuclein processing, and neurodegeneration

• Alzheimer's disease applications:

  • Study RER1's role in regulating APP trafficking and processing

  • Investigate how RER1-mediated retention of γ-secretase affects Aβ production

  • Develop potential therapeutic strategies targeting RER1 to modulate Aβ generation

• Experimental models:

  • Transgenic animals with modified RER1 expression

  • Patient-derived iPSCs differentiated into relevant neural types

  • Organoid models mimicking disease pathology

Research has shown that RER1 influences the trafficking and localization of both γ-secretase and APP, thereby regulating the production and secretion of Aβ peptides . These findings suggest that targeting RER1 could represent a novel approach for modulating pathogenic protein accumulation in neurodegenerative diseases.

What methods can be used to investigate RER1 function in hybrid yeast species like Saccharomyces pastorianus?

Studying RER1 in the hybrid brewing yeast S. pastorianus presents unique challenges and opportunities:

• Genomic considerations:

  • S. pastorianus contains DNA from both S. cerevisiae and S. bayanus

  • Different strains contain varying ratios of parental genomes

  • Group 1 strains contain approximately one genome each of S. cerevisiae and S. bayanus

  • Group 2 strains contain approximately two genomes of S. cerevisiae and one genome of S. bayanus

• Genetic engineering approaches:

  • CRISPR-Cas9 editing targeting specific "landing sites" on chimeric chromosomes

  • Integration of expression cassettes at safe genomic locations

  • Selection of appropriate promoters for target expression levels

• Functional analysis methods:

  • Complementation studies using RER1-deficient yeast strains

  • Protein localization studies comparing parental and hybrid species

  • Trafficking assays to assess differences in secretory pathway function

The unique genomic architecture of S. pastorianus requires careful consideration when designing experiments, particularly when targeting genes that may be present in multiple copies or different versions from each parental genome.

How can protein-protein interaction networks involving RER1 be comprehensively mapped?

To elucidate the complete interactome of RER1, researchers should employ complementary approaches:

• Unbiased screening methods:

  • Yeast two-hybrid screening with RER1 as bait

  • Proximity-dependent biotin identification (BioID)

  • APEX2-based proximity labeling

  • Immunoprecipitation coupled with mass spectrometry

• Validation techniques:

  • Co-immunoprecipitation with specific antibodies

  • Fluorescence resonance energy transfer (FRET)

  • Bimolecular fluorescence complementation (BiFC)

  • Surface plasmon resonance for quantitative binding measurements

• Network analysis:

  • Pathway enrichment analysis of identified interactors

  • Comparison with known secretory pathway components

  • Functional clustering of interaction partners

RER1 has been identified as an interactor with γ-secretase components including Nicastrin (NCT) and Presenilin enhancer 2 (PEN2) . A comprehensive understanding of RER1's interaction network would provide valuable insights into its diverse roles in cellular trafficking and disease pathways.

How might RER1 be utilized in developing novel therapeutic approaches for neurodegenerative diseases?

RER1's role in protein trafficking presents several potential therapeutic avenues:

• Therapeutic targeting strategies:

  • Small molecule modulators of RER1-substrate interactions

  • Peptide-based inhibitors mimicking binding interfaces

  • Gene therapy approaches to increase RER1 expression in affected tissues

• Disease-specific applications:

  • For Parkinson's disease: Enhancing RER1 activity to reduce alpha-synuclein accumulation

  • For Alzheimer's disease: Modulating RER1-mediated retention of γ-secretase to reduce Aβ production

• Delivery considerations:

  • Viral vectors (AAV, lentiviral) for CNS delivery

  • Blood-brain barrier penetration strategies for small molecules

  • Cell-based delivery systems (stem cells expressing RER1)

The Michael J. Fox Foundation is currently supporting research to test whether viral expression of RER1 in the brain can reduce alpha-synuclein pathology and associated neurodegeneration in pre-clinical models of parkinsonism . If successful, this approach could lead to the development of new drugs targeting RER1 for treatment of Parkinson's disease.

What comparative approaches can reveal evolutionary insights about RER1 function across species?

To understand RER1's evolutionary conservation and functional divergence:

• Comparative genomic analyses:

  • Sequence alignment of RER1 homologs across evolutionary distant species

  • Identification of conserved domains and species-specific adaptations

  • Synteny analysis to examine genomic context conservation

• Functional complementation studies:

  • Cross-species rescue experiments in RER1-deficient backgrounds

  • Domain-swapping between homologs to identify functional regions

  • Heterologous expression studies to assess trafficking differences

• Structural biology approaches:

  • Comparative modeling of RER1 structures across species

  • Conservation mapping onto predicted structural elements

  • Molecular dynamics simulations to assess functional movements

Human RER1 has been shown to complement the RER1 deletion mutant of Saccharomyces cerevisiae , indicating functional conservation across large evolutionary distances. This conservation suggests that findings from model organisms may be applicable to human health and disease.